CLGN - CollPlant Biotechnologies Ltd
Previous close
3.928
-0.270 -6.881%
Share volume: 9,443
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$4.20
-0.27
-0.06%
Fundamental analysis
13%
Profitability
18%
Dept financing
18%
Liquidity
44%
Performance
0%
Performance
5 Days
-6.44%
1 Month
8.40%
3 Months
-11.93%
6 Months
-22.37%
1 Year
-31.69%
2 Year
-51.45%
Key data
Stock price
$3.93
DAY RANGE
$3.86 - $4.21
52 WEEK RANGE
$3.60 - $6.75
52 WEEK CHANGE
-$31.69
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Yehiel Tal
Region: US
Website: collplant.com
Employees: 70
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: collplant.com
Employees: 70
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
CollPlant Biotechnologies Ltd. focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; AbbVie.
Recent news